Takeaways Thursdays vote lets pharmacies make these drugs, nothing more
These trials allow manufacturers to make specific and regulated health claims and provide doctors with guidelines about risks, side effects and who might be a viable candidate for the drug
It must not be misbranded, misused, relabeled, or represented as such
Both compounds were presented once in 24 hours and examined on days 1, 2, 4, 7, and 14
This is the central regulatory problem that full FDA approval would need to solve and it is the reason PCAC reviews for peptides like BPC-157 often hinge on available safety data rather than efficacy evidence from controlled human studies
Sikiric's lab in Croatia) No independent replication No competing research Raises red flags about bias Human data: ONE small retrospective study (not a randomized trial) No large-scale clinical trials No safety studies Unknown dosing Unknown side effects Recent systematic review (2024): Published in orthopaedic literature, concluded: "BPC-157 has potential based on preclinical data, but there is a concerning lack of published clinical trial data because studies appear to have been cancelled or stopped without publication." Reported Side Effects (From Online Users): Anonymous reports include: Injection site pain and swelling Joint pain Anxiety and panic attacks Heart palpitations Insomnia or drowsiness Fatigue and weakness Loss of appetite Depression and anhedonia (inability to feel pleasure) Note: These are anecdotal, not from clinical trials
